Roche’s faricimab hits the mark in diabetic macular edema study
Treatment demonstrated non-inferior visual acuity gains compared to Regeneron’s Eylea
Read More
Tag: Eylea
Bayer wins EU approval for Eylea syringe
The syringe provides a new streamlined method to administer Eylea
Read More
Beovu bags EU approval in wet AMD
The drug is the first EC-approved anti-VEGF treatment to demonstrate superior resolution of retinal fluid, compared to Bayer’s Eylea.
Read More
MHRA clarifies position on off-label Avastin
Roche’s drug has been used for years to treat wet AMD, an indication for which it is not specifically licensed
Read More
High Court rejects Novartis, Bayer’s bid to outlaw off-label Avastin
Bayer and Novartis have lost a landmark case in the UK seeking to prevent the off-label use of Roche’s Avastin to treat wet AMD, a leading cause of sight loss in the elderly.
Read More
NICE backs Bayer’s Eylea, Novartis’ Lucentis for sight condition
Cost regulators for NHS-funded therapies in England and Wales have issued updated guidelines for the treatment of wet AMD, which continue to back use of both Bayer’s Eylea and Novartis’ Lucentis, but the GMC says doctors should not fear prescribing Roche’s Avastin off-label if they believe it is clinically appropriate and in the patient’s best interest.
Read More
Regeneron calls time on Eylea/nesvacumab combo
Regeneron says that a combination of Eylea and nesvacumab being co-developed with Bayer will not move into Phase III testing for two eye conditions following disappointing Phase II data.
Read More
NICE nod for new Eylea indication
The National Institute for Health and Care Excellence (NICE) has issued a final positive recommendation for Bayer’s Eylea as a treatment for adults for the treatment of visual impairment due to myopic chorodial neovascularisation.
Read More
Novartis’ eye drug on par with Eylea but with fewer injections
Novartis’ eye drug brolucizumab has been proven in trials to be non-inferior to Regeneron/Bayer’s Elyea in treating vision loss in patients with neovascular age-related macular degeneration (nAMD), but with fewer injections than its rival.
Read More
Five medicines approved for use by NHS Scotland
Patients in Scotland with thyroid cancer and lung cancer are among those who will get routine NHS access to new treatment options for their illnesses after five medicines were accepted by the Scottish Medicines Consortium.
Read More
NICE backs Bayer’s Eylea to treat sight condition
Cost regulators have now published final guidance endorsing routine NHS use of Bayer’s Eylea for all patients with visual impairment due to branch retinal vein occlusion (BRVO), having initially recommended its use only in the second-line setting.
Read More
NICE widens scope of Bayer’s Eylea
Cost regulators are now backing NHS use of Bayer’s Eylea for all patients with visual impairment due to branch retinal vein occlusion (BRVO), having initially recommended its use only in the second-line setting.
Read More
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
